David Crean

MedicNova’s chief business officer details how changes at FDA are causing tension with the industry and investors, who are finding themselves less confident in the regulatory process.

David Crean, chief business officer at MedicNova, highlights bifurcation in regulatory processes at FDA.

MedicNova’s chief business officer David Crean explains how well-intentioned but poorly executed programs at FDA are causing tension between the agency and the industry.

Investors seeking predictability are adjusting their strategies in the current regulatory environment.

David Crean, chief business officer at MedicNova, discusses changes at FDA causing variability and unpredictability in regulatory approvals.